Cullinan Therapeutics, Inc.

By person

19 insiders · 213 transactions

12.0×

Nadim Ahmed holds 12.0 times base salary in stock. $8.43M of shares against $698.48K in salary for 2025.

Salary from the company's own proxy. The shares are what Nadim Ahmed last reported holding, valued at $21.57, the price Common Stock was last bought or sold at on the open market here, on 8 Sep 2026.

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

BVF PARTNERS L P/IL entity

10% owner

$21.30M (10)

—

+$21.30M

64,161

0.0997%

$1.38M

−98.5%

Lynx1 Capital Management LP entity

10% owner

$13.32M (8)

—

+$13.32M

8,963,500

13.93%

$193.34M

+26.4%

F2 Vision SCS

10% owner

—

$4.76M (7)

−$4.76M

1,255,963

1.95%

$27.09M

−56.9%

Michaelson Jennifer

Chief Scientific Officer

—

$4.71M (51) scheduled

−$4.71M

158,844

0.2468%

$3.43M

+537.2%

Jovan-Embiricos Morana

10% owner

$4.20M (2)

—

+$4.20M

312,565

0.4857%

$6.74M

—

Zawel Leigh

See Remarks

—

$3.09M (10)

−$3.09M

69,785

0.1084%

$1.51M

−53.4%

GADICKE ANSBERT

Director

$6.30M (1)

$8.85M (38)

−$2.55M

23,612,189

36.69%

$509.31M

+50.2%

Savill Corrine

Chief Business Officer

—

$2.54M (9) scheduled

−$2.54M

240,990

0.3745%

$5.20M

+24.8%

UBS Oncology Impact Fund L.P. entity

10% owner

$6.30M (1)

$7.77M (19)

−$1.47M

7,648,268

11.88%

$164.97M

—

F2 Bioscience I 2017 Ltd entity

10% owner

—

$1.30M (3)

−$1.30M

537,392

0.8350%

$11.59M

−15.9%

AHMED NADIM

President and CEO

$100.32K (1)

$794.17K (10)

−$693.85K

390,803

0.6073%

$8.43M

—

Trigilio Jeffrey

Chief Financial Officer

$47.25K (1)

$689.70K (13) scheduled

−$642.45K

133,919

0.2081%

$2.89M

—

Baeuerle Patrick

Chief Scientific Officer

—

$609.95K (2) scheduled

−$609.95K

417,434

0.6486%

$9.00M

+22.3%

Jones Jeffrey Alan

Chief Medical Officer

—

$309.61K (11)

−$309.61K

159,968

0.2486%

$3.45M

—

SUMER JACQUELYN L

Chief Legal Officer

—

$235.65K (11)

−$235.65K

130,559

0.2029%

$2.82M

+6,373%

Fenton Mary Kay

Chief Financial Officer

—

$59.90K (1)

−$59.90K

127,921

0.1988%

$2.76M

+6,293%

Hughes Owen

President and CEO

$52.50K (1)

—

+$52.50K

506,226

0.7866%

$10.92M

+0.5%

Ebeling Thomas

Director

—

186,653

0.2900%

$4.03M

+176.5%

Keane Raymond T

Chief Legal Officer

—

24,124

0.0375%

$520.35K

+1,385%

Individual transactions

Insider

Date

Role

Action

Price

Amount

Michaelson Jennifer

8 Sep 2026

Chief Scientific Officer

Sold after exercise

8,000

$21.57

$172.56K

Michaelson Jennifer

13 Aug 2026

Chief Scientific Officer

Sold after exercise

30,000

$20.26

$607.80K

Michaelson Jennifer

6 Jul 2026

Chief Scientific Officer

Sold after exercise

8,000

$17.82

$142.56K

Michaelson Jennifer

5 May 2026

Chief Scientific Officer

Sold after exercise

200

$15.58

$3.12K

Michaelson Jennifer

5 May 2026

Chief Scientific Officer

Sold after exercise

7,800

$14.60

$113.88K

Michaelson Jennifer

5 Mar 2026

Chief Scientific Officer

Sold after exercise

8,000

$15.68

$125.44K

Michaelson Jennifer

20 Feb 2026

Chief Scientific Officer

Sold after exercise

8,000

$14.30

$114.40K

Michaelson Jennifer

20 Feb 2026

Chief Scientific Officer

Sold after exercise

3,742

$13.62

$50.97K

Michaelson Jennifer

7 May 2024

Chief Scientific Officer

Sold after exercise

5,606

$30.06

$168.52K

Michaelson Jennifer

6 May 2024

Chief Scientific Officer

Sold after exercise

20,277

$28.54

$578.71K

Michaelson Jennifer

6 May 2024

Chief Scientific Officer

Sold after exercise

37,723

$27.82

$1.05M

Savill Corrine

1 Feb 2024

Chief Business Officer

Sold after exercise

40,000

$16.18

$647.20K

Savill Corrine

29 Jan 2024

Chief Business Officer

Sold after exercise

40,000

$14.09

$563.60K

Savill Corrine

23 Jan 2024

Chief Business Officer

Sold after exercise

21,316

$12.46

$265.60K

Savill Corrine

22 Jan 2024

Chief Business Officer

Sold after exercise

4,125

$12.02

$49.58K

Savill Corrine

22 Jan 2024

Chief Business Officer

Sold after exercise

14,559

$12.18

$177.33K

Michaelson Jennifer

7 Jun 2023

Chief Development Officer

Sold after exercise

100

$12.40

$1.24K

Michaelson Jennifer

6 Jun 2023

Chief Development Officer

Sold after exercise

11,900

$12.31

$146.49K

Michaelson Jennifer

25 Nov 2022

See Remarks

Sold after exercise

4,000

$13.30

$53.20K

Michaelson Jennifer

27 Sep 2022

See Remarks

Sold after exercise

4,000

$12.40

$49.60K

Michaelson Jennifer

8 Aug 2022

Chief Development Officer

Sold after exercise

1,385

$15.01

$20.79K

Michaelson Jennifer

25 Jul 2022

Chief Development Officer

Sold after exercise

8,000

$14.51

$116.08K

Michaelson Jennifer

18 Oct 2021

See Remarks

Sold after exercise

400

$23.61

$9.44K

Michaelson Jennifer

18 Oct 2021

See Remarks

Sold after exercise

204

$22.40

$4.57K

Michaelson Jennifer

18 Oct 2021

See Remarks

Sold after exercise

3,396

$21.10

$71.66K

Trigilio Jeffrey

15 Oct 2021

Chief Financial Officer

Sold after exercise

8,000

$25.00

$200.00K

Michaelson Jennifer

20 Sep 2021

See Remarks

Sold after exercise

800

$25.20

$20.16K

Michaelson Jennifer

20 Sep 2021

See Remarks

Sold after exercise

3,200

$24.34

$77.89K

Trigilio Jeffrey

8 Sep 2021

Chief Financial Officer

Sold after exercise

9,513

$28.85

$274.45K

Trigilio Jeffrey

8 Sep 2021

Chief Financial Officer

Sold after exercise

5,487

$27.83

$152.70K

Baeuerle Patrick

8 Sep 2021

See Remarks

Sold after exercise

11,000

$28.45

$312.95K

Michaelson Jennifer

18 Aug 2021

See Remarks

Sold after exercise

1,137

$28.07

$31.92K

Michaelson Jennifer

18 Aug 2021

See Remarks

Sold after exercise

2,863

$27.50

$78.73K

Baeuerle Patrick

10 Aug 2021

See Remarks

Sold after exercise

11,000

$27.00

$297.00K

Show all 213 transactions →

Cullinan Therapeutics, Inc.

By person

Individual transactions

What was left out